Symyx Joins MDL® Isentris Alliance
News May 04, 2006
Symyx Technologies, Inc. has joined the MDL® Isentris® Alliance. Collaborative efforts under the MDL Isentris Alliance are particularly important to research organizations and pharmaceutical companies that rely on multiple, specialized R&D software tools.
The ability to coordinate information flow between varieties of complex lab information systems is essential to effective, timely decision making.
"We're pleased that our partnership with Elsevier MDL will offer researchers more options for assembling informatics systems that utilize common, open technology platforms," said David Dorsett, General Manager of Symyx Software.
"The integration of the Symyx Software platform with the Isentris platform will be a welcome advantage to common customers and the research community."
Elsevier MDL Senior Vice President, Framework Development, Vikki Rehn, said, "The effective integration of research data and workflow applications offers R&D organizations a path to improved productivity."
"As major pharmaceutical research organizations move beyond industry-standard MDL ISIS technology to adopt the new-generation MDL Isentris platform, collaboration between leading informatics suppliers under the MDL Isentris Alliance enables rapid integration of specialty applications into a comprehensive research information system."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE